Executive Summary: Malaysia’s Biopharmaceutical Opportunity
For foreign investors seeking opportunities in Asia’s evolving life sciences sector, Malaysia offers a potential platform for biopharmaceutical manufacturing, technology transfer, research collaboration and regional commercial expansion.
The opportunity, however, lies not simply in entering an emerging industry, but in identifying where Malaysia’s industrial ambitions align with an investor’s capabilities, commercial objectives and long-term growth strategy.
Malaysia’s National Biotechnology Policy 2.0 identifies healthcare and wellbeing as a key priority, while the New Industrial Master Plan 2030 (NIMP 2030) highlights the need to develop Malaysia’s biologics manufacturing capabilities, including by leveraging biosimilar manufacturing and contract manufacturing.[1][2] These policy directions provide a basis for foreign investors to explore opportunities in Malaysia’s biopharmaceutical sector. The viability of any investment, however, will depend on the capabilities required for the proposed activity, compliance with applicable regulatory requirements and the project’s commercial feasibility.
From selecting an appropriate market-entry structure to navigating product registration, protecting intellectual property and structuring technology-transfer or manufacturing arrangements, legal considerations can directly affect an investment’s cost, risk and commercial value. Identifying these issues early can help investors avoid constraints on market entry, operational flexibility and the value of their investment.
1. Where Can Foreign Investors Participate?
Manufacturing and contract production
Biologics are medicines whose active substances are made by or derived from living organisms. Biosimilars are biological medicines demonstrated to be highly similar to an already registered reference product in terms of quality, safety and efficacy, in accordance with the applicable regulatory requirements.
NIMP 2030 identifies the need to develop Malaysia’s biologics manufacturing capabilities, while highlighting biosimilar manufacturing and contract manufacturing as potential ways to build those capabilities and reduce investment risks.[2] Foreign investors may explore different routes into the market, including establishing a new manufacturing facility, acquiring an existing operation, partnering with a local manufacturer or engaging a contract development and manufacturing organisation (CDMO).
Each approach has different implications. Establishing a facility provides greater control but requires substantial capital, technical expertise and regulatory preparation. Contract manufacturing may reduce initial investment, but requires careful management of third-party risks, particularly in relation to manufacturing quality, regulatory compliance and continuity of supply.
The legal arrangements must reflect these commercial realities. An investor should understand how responsibilities are allocated between the parties for quality standards, regulatory inspections, product recalls and manufacturing changes. It should also consider what happens if a manufacturer fails to meet the required standards or can no longer produce the medicine, including whether alternative manufacturing arrangements can be implemented and what regulatory approvals may be required.
A manufacturing agreement that addresses price and production volumes but overlooks these issues may expose the investor to significant disruption. For biologics, changes to manufacturing processes or production sites may also have regulatory implications. The agreement should therefore address change-control procedures, access to relevant manufacturing and quality records, audit rights, and the steps required to transfer production to another facility where necessary. For products dependent on specialised biological manufacturing processes, the ability to maintain supply and manage a transfer to an alternative facility can be as important as the original commercial terms.
Research, development and technology transfer
Foreign biotechnology companies may also explore collaborations with Malaysian research institutions, universities, biotechnology businesses and clinical research organisations.
These collaborations can provide access to scientific expertise and support product development, clinical research or the commercialisation of new technologies. However, the parties should agree at the outset who owns existing technology, who owns inventions arising from the collaboration and each party’s rights to use, license and commercialise the resulting intellectual property.
Technology transfer requires particular care. A biopharmaceutical business may depend on confidential manufacturing processes and technical know-how in addition to patents. An investor transferring technology to a Malaysian partner should therefore clearly define the scope of permitted use, ownership of and rights to improvements, and each party’s rights and obligations when the relationship ends.
The distinction between ownership and access is particularly important: a party may have permission to use technology without owning it, and ownership of a new invention does not necessarily confer unrestricted rights to use underlying third-party technology. Without appropriate protections, an investor could find that a collaboration intended to expand manufacturing capability creates uncertainty over intellectual property ownership, permitted use and continued access to essential technology. These matters should be resolved before the parties commit significant resources.
Market entry and commercial partnerships
Investors may also establish a Malaysian subsidiary, appoint a distributor or license products to a local partner. These options can provide access to the market without immediately establishing manufacturing operations.
The choice of structure should reflect the investor’s objectives, desired level of control, available resources and regulatory responsibilities. In particular, the parties should determine who will hold the product registration and be responsible for regulatory compliance, importation, distribution and ongoing product-safety obligations, including pharmacovigilance and product recalls.
A commercial agreement alone does not authorise a pharmaceutical product to be marketed in Malaysia. The proposed activities must be assessed against Malaysia’s regulatory requirements. In particular, investors should distinguish between contractual rights to distribute or commercialise a product and the regulatory approvals and licences required to place that product on the Malaysian market.
2. Government Policy and Investment Support
Malaysia’s biotechnology and industrial policies provide a useful starting point for investors evaluating potential opportunities. However, being part of a priority sector does not, by itself, confer eligibility for incentives, grants or other government support.
Investors should verify whether their proposed activities qualify under any relevant scheme and understand the conditions attached to approval. Eligibility may depend on factors such as the nature of the proposed activities, qualifying investment expenditure and any scheme-specific requirements.
This assessment has direct financial implications. A biopharmaceutical project may require substantial expenditure on facilities, specialised equipment, validation and skilled personnel before generating revenue. If the business model relies on an incentive, the investor should understand the approval conditions and the consequences if the expected benefit is not obtained.
Investors should also distinguish between an incentive being available under a scheme and a particular project being approved to receive it. Incentives should therefore be assessed alongside market demand, operating costs and regulatory feasibility, rather than treated as a substitute for a commercially viable business model.
3. The Legal Framework: What Investors Need to Know
Product registration and regulatory compliance
Medicinal products intended to be marketed in Malaysia are generally regulated under the Control of Drugs and Cosmetics Regulations 1984, made under the Sale of Drugs Act 1952. The Drug Control Authority (DCA) is established under those Regulations, with the National Pharmaceutical Regulatory Agency (NPRA) serving as its secretariat and undertaking regulatory functions[3]. The NPRA’s Drug Registration Guidance Document (DRGD) sets out requirements and guidance on product registration, quality control, inspection, licensing and post-registration matters, including specific guidance on biologics.[4]
The DRGD should be read together with the applicable legislation and regulations. The NPRA states that written law takes precedence over the DRGD in the event of any discrepancy. The applicable regulatory pathway depends on the product and the proposed activity. The NPRA has issued specific guidance for biosimilars and cell and gene therapy products, which may require particular regulatory evidence and planning[5]. Investors should assess the relevant requirements early, before committing to a manufacturing facility, acquisition or commercial partnership, as regulatory issues may affect investment costs and time to market.
Where clinical trials are contemplated, the applicable Malaysian requirements must also be considered. Depending on the trial and investigational product, a Clinical Trial Import Licence (CTIL) or Clinical Trial Exemption (CTX) may be required. The trial must also comply with applicable good clinical practice, ethics and other regulatory requirements.[6] The applicable trial authorisations and ethics requirements should be assessed as part of the development plan, rather than treated as administrative steps after the project has been designed.
Intellectual property and commercial protection
Intellectual property can be central to the value of a biopharmaceutical investment. Patents may protect inventions that meet the applicable legal requirements, while confidential know-how, manufacturing processes, trademarks and contractual rights may also be commercially important.
Investors should conduct appropriate due diligence to establish who owns the relevant rights, whether existing licences restrict their use and whether third-party rights could affect the proposed business. For an acquisition or technology-led investment, this should include checking whether the rights are owned by the intended transferor, whether they are subject to existing licences or security interests, and whether the intellectual property, know-how and supporting documentation needed to operate the business will remain available after completion.
The terms of technology licences and collaboration agreements are equally important. The parties should distinguish between technology brought into the relationship and improvements developed during it. They should also determine who owns new inventions, who may use the resulting technology and what rights survive termination.
These questions can determine whether an investor retains control over the assets that underpin its business. A well-structured agreement should protect proprietary information while allowing the parties to carry out their agreed activities. The objective is to ensure that the investor can lawfully use and commercialise the technology on which its business depends, while preserving appropriate protection for confidential information.
Investment structure and contractual risk
Investors may enter the Malaysian market through different structures, including establishing a Malaysian subsidiary, acquiring an existing business, forming a joint venture or entering into a licensing arrangement. The appropriate structure will depend on the investor’s commercial objectives, desired level of control, access to local capabilities and applicable regulatory requirements.
Due diligence should cover more than the target’s financial position. Depending on the transaction, it may need to examine regulatory status, material contracts, intellectual property ownership, existing liabilities and whether essential licences, approvals, contractual rights and operational capabilities can be maintained following completion, including where a change of ownership triggers consent or notification requirements.
The agreements should then allocate responsibility for product quality, regulatory compliance, supply commitments, product liability and dispute resolution mechanisms. For cross-border arrangements, the parties should consider the governing law and the practical enforceability of their contractual protections.
These matters are connected. An acquisition may provide rapid access to existing manufacturing capabilities, but unresolved regulatory issues or uncertain intellectual property rights can diminish the value of the transaction. A joint venture may provide local expertise, but unclear ownership of improvements or inadequate exit arrangements can restrict the investor’s future options.
The transaction documents should therefore be designed around the risks identified during due diligence, including the consequences of regulatory non-compliance, supply interruption, a change in control or the breakdown of the commercial relationship. Early legal assessment can help investors identify and address these risks before committing significant resources.
Conclusion: From Opportunity to Investment
Malaysia’s policy direction provides a foundation for foreign investors to explore opportunities in biopharmaceutical manufacturing, research collaboration, technology transfer and commercialisation. Turning that potential into a viable investment, however, requires more than identifying an attractive market or securing a local partner. Investors must ensure that their chosen business model is commercially sustainable, meets applicable regulatory requirements and protects the intellectual property and technology underpinning their competitive advantage.
These considerations are interconnected. The choice of investment structure can affect regulatory responsibilities; manufacturing and technology-transfer arrangements can determine continuity of supply and control over valuable know-how; and intellectual property protection can influence the long-term value of the investment.
For foreign investors considering Malaysia as part of their biopharmaceutical growth strategy, the most effective approach is to assess commercial, regulatory and legal considerations together from the outset. This integrated approach can help investors identify viable entry routes, protect valuable assets and structure partnerships that remain workable as the business develops, enabling them to navigate Malaysia’s biopharmaceutical landscape with greater clarity and confidence.
For further information, please contact:
Dato’ Azmi Mohd Ali, Partner, Azmi & Associates
Footnotes and references:
- Malaysian Bioeconomy Development Corporation, National Biotechnology Policy 2.0 (DBN 2.0). Official policy information: Bioeconomy Corporation — National Biotechnology Policy 2.0.
- Ministry of Investment, Trade and Industry (MITI), New Industrial Master Plan 2030, Sector 4: Pharmaceutical Industry. Official sectoral plan (PDF).
- https://www.npra.gov.my/easyarticles/images/users/1047/DCA/DCA-Term-of-Reference_May-2023.pdf
- Sale of Drugs Act 1952; Control of Drugs and Cosmetics Regulations 1984; National Pharmaceutical Regulatory Agency (NPRA), Drug Registration Guidance Document (DRGD), 3rd ed., 12th rev. (July 2026). Available at: https://www.npra.gov.my/index.php/en/drug-registration-guidance-documents-drgd-e-book.html.
- National Pharmaceutical Regulatory Agency (NPRA), Guidance Document and Guidelines for Registration of Biosimilars in Malaysia (February 2024); Guidance Document and Guidelines for Registration of Cell and Gene Therapy Products (CGTPs) in Malaysia (October 2025). Official NPRA biologics guidance.
- National Pharmaceutical Regulatory Agency (NPRA), Malaysian Guidelines for Good Clinical Practice, 5th Edition (2026); and Malaysian Guideline for Application of Clinical Trial Import Licence (CTIL) and Clinical Trial Exemption (CTX), 8.1th Edition (effective 30 April 2025). The fifth edition of the Good Clinical Practice Guidelines came into effect on 1 February 2026, with a transition period until 31 December 2026. Full compliance is mandatory from 1 January 2027. Official NPRA clinical-trial guidance.
